Farther Finance Advisors’s Astria Therapeutics ATXS Stock Holding History

Farther Finance Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,640	Closed	-$73.8K	–	5760
2025 Q4	$73.8K	Sell	5,640 -1,053	-16%	-$12.6K	﹤0.01%	2542
2025 Q3	$48.7K	Buy	6,693 +1,222	+22%	+$8.27K	﹤0.01%	2456
2025 Q2	$29.3K	Buy	5,471 +3,557	+186%	+$17.2K	﹤0.01%	2435
2025 Q1	$10.3K	Buy	+1,914	New	+$13.4K	﹤0.01%	2722

Farther Finance Advisors's ATXS Position: Q1 2026 in Review

Farther Finance Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 5,640 shares — an estimated $73.8K sold.

Farther Finance Advisors first reported a position in ATXS in Q1 2025 and held it in 4 quarters. The position peaked at $73.8K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Farther Finance Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Farther Finance Advisors sold 5,640 Astria Therapeutics shares in Q1 2026, an estimated $73.8K.
Farther Finance Advisors first reported a position in Astria Therapeutics in Q1 2025 and held it in 4 quarters.
Farther Finance Advisors's Astria Therapeutics position peaked at $73.8K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.